Share this video  

ASCO 2022 | SerOzNET study: SARS-CoV-2 post-vaccine surveillance study in Australian patients with cancer

Vaccinations against SARS-CoV-2 have proven to be effective at protecting people from severe cases of COVID-19. However, patients with cancer have been excluded from clinical trials investigating the vaccines safety and efficacy and early data has suggested patients who are immunosuppressive experience a worse response. Eva Segelov, MBBS, PhD, FRACP, Monash University, Melbourne, Australia, discusses the prospective, observational study, SerOzNET (ACTRN12621001004853), conducted with the aim to improve understanding of the safety and efficacy of the COVID-19 vaccines in patients with specific cancers, enrolling adults and children with cancer receiving the COVID-19 vaccine. The study was carried out in Australia where, at the time of study commencement, there was a low number of COVID-19 cases and little vaccination distribution, providing unique conditions to explore vaccine-related immunity in various cancer cohorts. Quality-of-life, patient-reported toxicity, and vaccine hesitancy were assessed. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.